Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Ribomic Aims to Commercialize Non-Addictive Analgesic Nucleic Acid Drug
August 30, 2012
- Takeda to Start Local Manufacturing at New Russian Factory around FY2014
August 30, 2012
- IBL, IBR to Codevelop Vaccines Using Transgenic Silkworms
August 30, 2012
- Torii to Exclusively Market JT’s Novel Anti-HIV Drug in Japan
August 30, 2012
- GSK Launches ReQuip CR Tablets; MHLW Recommends Use
August 30, 2012
- Takeda Less Dependent on Japan, US Revenues Due to Expanding Emerging Market Biz: CCO Morich
August 29, 2012
- Takeda Gearing Up for Emerging Market Operations
August 29, 2012
- MTPC, Daiichi Sankyo to Launch DPP-4 Inhibitor Tenelia on Sept. 10
August 29, 2012
- Izumo, Former VP of Novartis Institutes for BioMedical Research, Appointed Head of Takeda’s MD Drug Discovery Unit
August 29, 2012
- JT’s Licensee Obtains US Approval for Combination Tablet Containing JTK-303
August 29, 2012
- Nichi-Iko Voluntarily Recalls Lansoprazole OD Tablets 15 mg
August 29, 2012
- Daiichi Sankyo, Eli Lilly Not to Apply for Prasugrel for ACS in the US, Europe
August 29, 2012
- Major US, European Pharmaceutical Makers Faced with “Patent Cliffs”
August 28, 2012
- Plavix Approved for STEMI: sanofi-aventis
August 28, 2012
- Strattera Approved as 1st Adult ADHD Treatment in Japan: Eli Lilly Japan
August 28, 2012
- Growject Approved for SGA Dwarfism: JCR
August 28, 2012
- Large Portfolio, Competitive Prices, High Quality to Be Key to Success in Generics Business: Mr Bourla of Pfizer
August 27, 2012
- Japanese Ethical Drug Market Expands by 2.1% in Apr-Jun 2012: IMS Japan
August 27, 2012
- Diovan Approved for Pediatric Hypertension; Japan’s 1st ARB Approved for Pediatric Indication: Novartis
August 27, 2012
- Kyowa Kirin Initiates PII trial of Mogamulizumab in Europe, the US
August 27, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…